Special Issue "New Insights into Myeloproliferative Neoplasms"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 30 June 2020.
Interests: chronic myeloproliferative neoplasms (MPNs); gene expression profiling; epigenetics; SNPs; immune cell and molecular studies in MPNs; epidemiological studies; interferon-alpha2 (IFN-alpha2); statins; ruxolitinib in the treatment of MPNs
In recent years, new insights into the Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) have emerged, including the important role of chronic inflammation as the driving force for clonal evolution and disease progression and the impact of chronic inflammation upon symptom burden as well. The role of interferon-alfa2 (IFN) in the initial treatment of MPNs has been increasingly recognized, being fueled by the EU marketing authorization for RopegInterferon Alfa2b (BesremiR) as first line monotherapy in adults for the treatment of PV without symptomatic splenomegaly. The “wait and watch strategy” in low-risk patients is currently being challenged, since treatment with IFN may induce minimal residual disease (MRD) with low-burden JAK2V617F and normal bone marrow after about five years of IFN-treatment. Next generation sequencing is being used increasingly at the time of diagnosis for early prognostication and guidance for treatment. Most recent studies have unraveled MPNs to be far more prevalent than previously recognized, underscoring the unmet need of much earlier diagnosis of MPNs by molecular screening of patients at risk of having undiagnosed MPNs. This might also imply an earlier diagnosis of second cancers which MPN-patients are prone to develop, likely as a consequence of chronic inflammation, immunoderegulation and associated defective tumor immune surveillance.
This Special Issue will highlight several of the above issues, including mathematical modelling studies, substantiating the proof of concept for chronic inflammation as a trigger and driver of MPN development, and underscoring the importance of initiating IFN-treatment as early as possible. A new bright future for patients with MPNs is foreseen, in whom early intervention with stem cell targeted therapy (IFN) or IFN in combination with agents targeting the chronic inflammatory state (e.g., ruxolitinib and statins) may open the avenue for many more patients to follow the path towards MRD, and even cure being obtained by vaccination strategies.
Prof. Dr. Hans Hasselbalch
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Philadelphia-negative myeloproliferative neoplasms (MPNs)
- chronic inflammation
- comorbidity burden
- quality of life
- early diagnosis and treatment
- immune therapy
- minimal residual disease